Add to ORKGStereotactic body radiation therapy (SBRT) offers excellent local control of early-stage non-small cell lung cancer (NSCLC), but there currently is a need for tolerable systemic therapy to address regional and distant disease progression. One potential option is immunotherapy, which in metastatic NSCLC has shown promise for sustained disease control in a subset of patients. There is also growing evidence for a clinical synergy between radiation and immunotherapy, with several ongoing trials studying the abscopal effect. This review summarizes the current data in the fast-changing field of immuno-radiation therapy, highlighting updates from recent clinical trials
Metastatic non-small cell lung cancer (NSCLC) is associated with a limited survival when treated wit...
Background About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at init...
BACKGROUND: About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at init...
Immunotherapy has revolutionized the treatment of metastatic non-small cell lung cancer (NSCLC). Oli...
The current standard of care for locally advanced non-small cell lung cancer (NSCLC) includes radiat...
An immunophenotyping analysis was performed in peripheral blood samples from seven patients with lun...
Background: Several immunotherapy (IT) agents are FDA approved for treatment of melanoma and non-sma...
Background: Immune checkpoint inhibitors (ICI) have represented a revolution in the treatment of non...
Immunotherapy has revolutionized the treatment of metastatic non-small cell lung cancer (NSCLC). Oli...
Stereotactic body radiation therapy (SBRT) allows for the non-invasive and precise delivery of ablat...
Stereotactic body radiation therapy (SBRT) is a newly developed technique currently in clinical use....
For many years, conventional oncologic treatments such as surgery, chemotherapy, and radiotherapy (R...
Background: To define efficacy and toxicity of Immunotherapy (IT) with stereotactic radiotherapy (SR...
Copyright © 2013 Jing Zeng et al.This is an open access article distributed under theCreative Common...
Methods of harnessing the immune system to treat cancer have been investigated for decades, but yiel...
Metastatic non-small cell lung cancer (NSCLC) is associated with a limited survival when treated wit...
Background About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at init...
BACKGROUND: About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at init...
Immunotherapy has revolutionized the treatment of metastatic non-small cell lung cancer (NSCLC). Oli...
The current standard of care for locally advanced non-small cell lung cancer (NSCLC) includes radiat...
An immunophenotyping analysis was performed in peripheral blood samples from seven patients with lun...
Background: Several immunotherapy (IT) agents are FDA approved for treatment of melanoma and non-sma...
Background: Immune checkpoint inhibitors (ICI) have represented a revolution in the treatment of non...
Immunotherapy has revolutionized the treatment of metastatic non-small cell lung cancer (NSCLC). Oli...
Stereotactic body radiation therapy (SBRT) allows for the non-invasive and precise delivery of ablat...
Stereotactic body radiation therapy (SBRT) is a newly developed technique currently in clinical use....
For many years, conventional oncologic treatments such as surgery, chemotherapy, and radiotherapy (R...
Background: To define efficacy and toxicity of Immunotherapy (IT) with stereotactic radiotherapy (SR...
Copyright © 2013 Jing Zeng et al.This is an open access article distributed under theCreative Common...
Methods of harnessing the immune system to treat cancer have been investigated for decades, but yiel...
Metastatic non-small cell lung cancer (NSCLC) is associated with a limited survival when treated wit...
Background About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at init...
BACKGROUND: About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at init...